A pharmaceutical composition for treating leukemia, including by weight 2 to 8% of realgar, 25 to 42% of indigo naturalis, 50 to 60% of salvia miltiorrhiza, and 6 to 10% of heterophylla.

A pharmaceutical composition for treating leukemia, including by weight 2 to 8% of realgar, 25 to 42% of indigo naturalis, 50 to 60% of salvia miltiorrhiza, and 6 to 10% of heterophylla.

An object of the present invention is to provide a composition that is effective in maintenance, enhancement, improvement, etc. of a cognitive function. The present invention provides a composition comprising a hop oxidation-reaction product for maintaining, enhancing, and/or improving a cognitive function. The cognitive functions include memory function and attention or concentration function.

A medicament for use in treating tuberculosis, the medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

A medicament for use in treating tuberculosis, the medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

A medicament for use in treating tuberculosis, the medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.

Provided are a method and use of microRNA MiR-2911 in regulating an ebola virus. Particularly provided are a method and use of isolated microRNA MiR-2911 in regulating an ebola virus protein gene.

Provided are a method and use of microRNA MiR-2911 in regulating an ebola virus. Particularly provided are a method and use of isolated microRNA MiR-2911 in regulating an ebola virus protein gene.

A pharmaceutical or cosmetic composition is provided. The composition includes an Indigo Naturalis or Indigo-producing plant extract, for inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. A method of inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, is also provided. The method includes contacting a cell with an effective amount of an Indigo Naturalis or Indigo-producing plant extract.

A pharmaceutical or cosmetic composition is provided. The composition includes an Indigo Naturalis or Indigo-producing plant extract, for inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. A method of inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, is also provided. The method includes contacting a cell with an effective amount of an Indigo Naturalis or Indigo-producing plant extract.